Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease | Zendy

William R. Hiatt | Zendy; F. Gerry R. Fowkes | Zendy; Gretchen Heizer | Zendy; Jeffrey S. Berger | Zendy; Iris Baumgärtner | Zendy; Peter Held | Zendy; Brian G. Katona | Zendy; Kenneth W. Mahaffey | Zendy; Lars Norgren | Zendy; W. Schuyler Jones | Zendy; Juuso Blomster | Zendy; Marcus Millegård | Zendy; Martin Craig | Zendy; Manesh R. Patel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

Author(s) -

William R. Hiatt,

F. Gerry R. Fowkes,

Gretchen Heizer,

Jeffrey S. Berger,

Iris Baumgärtner,

Peter Held,

Brian G. Katona,

Kenneth W. Mahaffey,

Lars Norgren,

W. Schuyler Jones,

Juuso Blomster,

Marcus Millegård,

Martin Craig,

Manesh R. Patel

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1611688

Subject(s) - medicine , clopidogrel , ticagrelor , aspirin , peripheral , arterial disease , cardiology , adverse effect , coronary artery disease , disease , platelet aggregation inhibitor , vascular disease

Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research